JPG - 27.6 kb
JPG - 5.6 kb

In May 2009, the Air France KLM Group and Delta Air Lines signed an agreement to jointly operate their trans-Atlantic routes, thereby sharing revenues and costs in a joint venture. The relationship was expanded in July 2010 to include Alitalia and now generates annual revenues estimated at more than $10 billion. Together, Delta-Air France-KLM-Alitalia operate 248 daily flights between 26 North American gateways and 33 cities in Europe alone. Representing 26% of the capacity across the Atlantic, the joint venture is the natural trans-Atlantic leader. Most importantly, the joint venture partners provide customers with a wider choice of flights and more convenient flight times through their vast network centered on 6 major hubs, including Atlanta Hartsfield-Jackson. Worldwide, the group serves close to 300 destinations in North America, 200 destinations in Europe, Asia and Latin America, and offers competitive fares, as well as a seamless travel experience throughout the joint venture network, from lounges to transferring between flights, to providing the best-in-class service to their customers. For more information visit:


Celebrating creativity, chaos and teamwork since 2001, MailChimp is an email marketing service provider to manage contacts, send marketing emails and track results. It has more than 8 million users that collectively sends over 10 billion emails through the service each month.

Nissan is among the world’s leading car manufacturers, supplying the automobile market across the five continents. The multinational Japanese company has developed a partnership with French automaker Renault in 1999.Today, the automobile company continues to expand its international market and participates in shaping our future by developing groundbreaking technological products.


Rubicon Global is a waste and recycling company focused on sustainability. The Atlanta-based company was founded on a bold idea: to disrupt the waste and recycling industry and create less expensive, more sustainable solutions.


Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead’s portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.